Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening
Interview with Nora Pashayan, BSc MSc MSt MD PhD FFPH, author of Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"JAMA Oncology Author Interviews","authorlink":""},"src":"http:\/\/traffic.libsyn.com\/jamaoncologyauthorinterviews\/Cost-effectiveness_and_Benefit-to-Harm_Ratio_of_Risk-Stratified_Breast_Cancer_Screening.mp3?dest-id=422099","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202106\/b009a0-4018-1e89-410c1c_800.jpg"},"title":"Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening","link":"javascript:;","id":"item-437992"}]
